130 results on '"Maboko L"'
Search Results
2. Priming with a 'simplified regimen' of HIV-1 DNA vaccine is as good as a 'standard regimen' when boosted with heterologous HIV-1 MVA vaccine
- Author
-
Munseri P, Kroidl A, Nilsson C, Moshiro C, Aboud S, Joachim A, Geldmacher C, Aris E, Buma D, Lyamuya E, Gotch F, Godoy-Ramirez K, Pallangyo K, Maboko L, Marovich M, Robb M, Hoelscher M, Janabi M, Mann P, Joseph S, Mfinanga S, Stoehr W, Mhalu F, Wahren B, Biberfeld G, McCormack S, Sandstrom E, and Bakari M
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2012
- Full Text
- View/download PDF
3. Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
- Author
-
Podola L, Bauer A, Haule A, Sudi L, Nilsson C, Godoy-Ramirez K, Mann P, Missanga M, Kaluwa B, Maboko L, Lueer C, Mwakatima M, Aboud S, Bakari M, Currier J, Robb M, McCormack S, Joseph S, Lyamuya E, Hoelscher M, Wahren B, Sandström E, Biberfeld G, Geldmacher C, and Kroidl A
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2012
- Full Text
- View/download PDF
4. Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
- Author
-
Bauer A, Podola L, Haule A, Sudi L, Nilsson C, Mann P, Missanga M, Kaluwa B, Maboko L, Lueer C, Mwakatima M, Aboud S, Bakari M, Currier J, Robb M, Joseph S, McCormack S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Kroidl A, and Geldmacher C
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2012
- Full Text
- View/download PDF
5. Characterization of envelope function of transmitted viruses circulating in Mbeya, Tanzania, and its impact on disease progression
- Author
-
Nofemela A, Bandawe G, Thebus R, Marais J, Maboko L, Hoelscher M, Williamson C, and Woodman Z
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2012
- Full Text
- View/download PDF
6. High prevalence of ECG variations and abnormalities in young and healthy TaMoVac 01 HIV vaccine trial volunteers from Tanzania
- Author
-
Mann PJ, Munseri P, Kaluwa B, Missanga M, Lwakatare J, Hoelscher M, Bakari M, Janabi M, Maboko L, Sandström E, and Kroidl A
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2012
- Full Text
- View/download PDF
7. P08-03. Genetic complexity of TRIM5 and APOBEC in East Africa
- Author
-
Michael NL, Robb ML, Wabwire-Mangen F, Maboko L, Hoelscher M, Kibuuka H, Eller M, Eller L, Bautista C, Moqueet N, Koehler R, Perret K, Walsh AM, McCutchan F, Kim J, and Kijak GH
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2009
- Full Text
- View/download PDF
8. S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania
- Author
-
McCutchan FE, Michael NL, Robb ML, Hoelscher M, Maboko L, Ratto-Kim S, Moqueet N, Bautista CT, Currier JR, Saathoff E, Walsh AM, Koehler RN, Kim JH, and Kijak GH
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2009
- Full Text
- View/download PDF
9. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis
- Author
-
Boehme, C., Molokova, E., Minja, F., Geis, S., Loscher, T., Maboko, L., Koulchin, V., and Hoelscher, M.
- Published
- 2005
- Full Text
- View/download PDF
10. Methodological lessons from a cohort study of high risk women in Tanzania
- Author
-
Hoffmann, O, Zaba, B, Wolff, B, Sanga, E, Maboko, L, Mmbando, D, von Sonnenburg, F, and Hoelscher, M
- Published
- 2004
11. Baseline survey of sexually transmitted infections in a cohort of female bar workers in Mbeya Region, Tanzania
- Author
-
Riedner, G, Rusizoka, M, Hoffmann, O, Nichombe, F, Lyamuya, E, Mmbando, D, Maboko, L, Hay, P, Todd, J, Hayes, R, Hoelscher, M, and Grosskurth, H
- Published
- 2003
12. Baseline survey sexually transmitted infections in a cohort of female bar workers in Mbeya Region, Tanzania
- Author
-
Riedner, G, Rusizoka, M, Hoffmann, O, Nichombe, F, Lyamuya, E, Mmbando, D, Maboko, L, Hay, P, Todd, J, Hayes, R, Hoelscher, M, and Grosskurth, H
- Subjects
Sexually transmitted diseases -- Demographic aspects -- Analysis ,Prevalence studies (Epidemiology) -- Analysis ,Health ,Analysis ,Demographic aspects - Abstract
Objectives: To determine baseline prevalence of sexually transmitted infections (STI) and other reproductive tract infections (RTI) and their association with HIV as well as sociodemographic and behavioural characteristics in a [...]
- Published
- 2003
13. Towards host-directed therapies for tuberculosis [Comment]
- Author
-
Zumla, A., Chakaya, J., Hoelscher,M., Ntoumi, F., Rustomjee, R., Vilaplana, C., Yeboah-Manu, D., Rasolofo, V., Munderi, P., Singh, N., Aklillu, E., Padayatchi, N., Macete, E., Kapata, N., Mulenga, M., Kibiki, G., Mfinanga, S., Nyirenda, T., Maboko, L., Garcia-Basteiro, A., Rakotosamimanana, N., Bates, M., Mwaba, P., Reither, K., Gagneux, S., Edwards, S., Mfinanga, E., Abdulla, S., Cardona, P.J., Russell, J.B.W., Gant, V., Noursadeghi, M., Elkington, P., and Bonnet, Maryline
- Published
- 2016
14. A continuously monitored colorimetric method for detection of Mycobacterium tuberculosis complex in sputum
- Author
-
Rojas-Ponce, G, Rachow, A, Guerra, H, Mapamba, D, Joseph, J, Mlundi, R, Marimoto, S, Ntinginya, NE, Mangu, C, Framhein, A, Butler, A, Kohlenberg, A, Ngatemelela, D, Froeschl, G, Maboko, L, Hoelscher, M, and Heinrich, N
- Subjects
treatment monitoring ,2-3-diphenyl-5-thienyl-(2)-tetrazolium STC ,liquid culture ,purl.org/pe-repo/ocde/ford#3.03.08 [https] ,nitrate reductase assay ,TTD - Abstract
OBJECTIVE: To develop a new liquid culture Method: to detect Mycobacterium tuberculosis complex (MTC) in sputum using 2,3-diphenyl-5-thienyl-(2)-tetrazolium (STC), the nitrate reductase assay (NRA) and p-nitrobenzoic acid (PNB). DESIGN: Ninety-three sputum samples collected from 18 tuberculosis patients were decontaminated with N-acetyl-L-cysteine-sodium hydroxide using MGIT™ 960 and in STC-NRA cultures, both in the presence and in the absence of PNB, an inhibitor of MTC growth. The reduction of STC by colour change indicated mycobacterial growth; NRA was then performed to confirm MTC. RESULTS: STC-NRA culture was positive for acid-fast bacilli in 66/93 (71%) samples, of which 60/93 (64.5%) were identified as MTC-positive and 6/93 (6.5%) as indeterminate mycobacteria. MGIT indicated MTC in 59/93 (63.4%) cultures. Contamination was detected in 12/93 (13%) STC-NRA cultures vs. 29/93 (31.2%) MGIT cultures. The mean time to detection (TTD) of MTC using STC-NRA was 14 days and 7 days using MGIT. CONCLUSION: The STC-NRA Method: is sensitive for the detection of MTC in sputum. TTD increased with duration of anti-tuberculosis treatment, highlighting the value of this Method: in monitoring treatment success. The Method: is simple and inexpensive and, unlike MGIT, does not require technical equipment. The preliminary performance characteristics of the Method: should be further evaluated in larger studies.
- Published
- 2013
15. Risk factors for HIV-1 infection in a vaccine preparedness cohort study in Mbeya Region, Tanzania
- Author
-
Geis, S, Saathoff, E, Geldmacher, C, Hoffmann, O, Mmbando, D, Samky, E, Sanga, I, McCutchan, F, Robb, M, Michael, N, Maboko, L, and Hoelscher, M
- Subjects
ddc: 610 ,virus diseases ,610 Medical sciences ,Medicine - Abstract
Introduction: Despite many advances in HIV prevention, treatment and care HIV⁄AIDS continues to be a significant cause of morbidity and mortality worldwide, particularly in Africa. Hence, the development of an effective HIV vaccine remains an urgent priority. A vaccine preparedness cohort[for full text, please go to the a.m. URL], 10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)
- Published
- 2010
- Full Text
- View/download PDF
16. 'Baseline Survey of Sexually Transmitted Infections in a Cohort of Female Bar Workers in Mbaya Region,Tanzania
- Author
-
Riedner, G, Rusizoka, M, Hoffmann, O, Nichombe, F, Lyamuya, E, Mmbando, D, Maboko, L, Hay, P, Todd, J, Hayes, R, Hoelscher, M, and Grosskurth, H
- Subjects
Sexually transmitted infections ,virus diseases ,urologic and male genital diseases - Abstract
To determine baseline prevalence of sexually transmitted infections (STI) and other reproductive tract infections (RTI) and their association with HIV as well as sociodemographic and behavioural characteristics in a newly recruited cohort of female bar workers in Mbeya Region, Tanzania. 600 female bar workers were recruited from 17 different communities during September to November 2000 and underwent gynaecological examination, laboratory testing for HIV/STI, and interviews using structured questionnaires. Results: HIV-1 seroprevalence was 68%. Prevalences of STI/RTI were high titre syphilis (TPPA/RPR >1/8), 9%; herpes simplex virus 2 antibodies, 87%; chlamydia, 12%; gonorrhoea, 22%; trichomoniasis, 24%;and bacterial vaginosis, 40%. HIV infection was associated with TPPA and HSV-2 seropositivity, bacterial vaginosis and clinically diagnosed genital ulcers, blisters, and warts. Reported high risk sexual behavior during the past year (having multiple casual partners) was associated with prevalent STI. Female bar workers in Mbeya are at high risk of STI and HIV infection. Targeted STI/HIV prevention interventions for these women and their sexual partners need to be reinforced. Methods should be sought to improve healthcare seeking and to provide easily accessible and affordable STI care services.
- Published
- 2003
17. A continuously monitored colorimetric method for detection of Mycobacterium tuberculosis complex in sputum
- Author
-
Rojas-Ponce, G., primary, Rachow, A., additional, Guerra, H., additional, Mapamba, D., additional, Joseph, J., additional, Mlundi, R., additional, Marimoto, S., additional, Ntinginya, N. E., additional, Mangu, C., additional, Framhein, A., additional, Butler, A., additional, Kohlenberg, A., additional, Ngatemelela, D., additional, Froeschl, G., additional, Maboko, L., additional, Hoelscher, M., additional, and Heinrich, N., additional
- Published
- 2013
- Full Text
- View/download PDF
18. Performance of the Xpert® MTB/RIF assay in an active case-finding strategy: a pilot study from Tanzania [Short communication]
- Author
-
Ntinginya, E. N., primary, Squire, S. B., additional, Millington, K. A., additional, Mtafya, B., additional, Saathoff, E., additional, Heinrich, N., additional, Rojas-Ponce, G., additional, Kowuor, D., additional, Maboko, L., additional, Reither, K., additional, Clowes, P., additional, Hoelscher, M., additional, and Rachow, A., additional
- Published
- 2012
- Full Text
- View/download PDF
19. P08-03. Genetic complexity of TRIM5 and APOBEC in East Africa
- Author
-
Walsh, AM, primary, Perret, K, additional, Koehler, R, additional, Moqueet, N, additional, Bautista, C, additional, Eller, L, additional, Eller, M, additional, Kibuuka, H, additional, Hoelscher, M, additional, Maboko, L, additional, Wabwire-Mangen, F, additional, Robb, ML, additional, Michael, NL, additional, McCutchan, F, additional, Kim, J, additional, and Kijak, GH, additional
- Published
- 2009
- Full Text
- View/download PDF
20. S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania
- Author
-
Koehler, RN, primary, Walsh, AM, additional, Saathoff, E, additional, Currier, JR, additional, Bautista, CT, additional, Moqueet, N, additional, Ratto-Kim, S, additional, Maboko, L, additional, Hoelscher, M, additional, Robb, ML, additional, Michael, NL, additional, McCutchan, FE, additional, Kim, JH, additional, and Kijak, GH, additional
- Published
- 2009
- Full Text
- View/download PDF
21. Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in Tanzania
- Author
-
Riedner, G., primary, Todd, J., additional, Rusizoka, M., additional, Mmbando, D., additional, Maboko, L., additional, Lyamuya, E., additional, Hoffmann, O., additional, MacLean, I, additional, Grosskurth, H., additional, and Hayes, R., additional
- Published
- 2006
- Full Text
- View/download PDF
22. In-Depth Analysis of a Heterosexually Acquired Human Immunodeficiency Virus Type 1 Superinfection: Evolution, Temporal Fluctuation, and Intercompartment Dynamics from the Seronegative Window Period through 30 Months Postinfection
- Author
-
McCutchan, F. E., primary, Hoelscher, M., additional, Tovanabutra, S., additional, Piyasirisilp, S., additional, Sanders-Buell, E., additional, Ramos, G., additional, Jagodzinski, L., additional, Polonis, V., additional, Maboko, L., additional, Mmbando, D., additional, Hoffmann, O., additional, Riedner, G., additional, von Sonnenburg, F., additional, Robb, M., additional, and Birx, D. L., additional
- Published
- 2005
- Full Text
- View/download PDF
23. In-Depth, Longitudinal Analysis of Viral Quasispecies from an Individual Triply Infected with Late-Stage Human Immunodeficiency Virus Type 1, Using a Multiple PCR Primer Approach
- Author
-
Gerhardt, M., primary, Mloka, D., additional, Tovanabutra, S., additional, Sanders-Buell, E., additional, Hoffmann, O., additional, Maboko, L., additional, Mmbando, D., additional, Birx, D. L., additional, McCutchan, F. E., additional, and Hoelscher, M., additional
- Published
- 2005
- Full Text
- View/download PDF
24. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis
- Author
-
Huggett Jim F, Saad Eiman, Kroidl Inge, Minja Lilian T, Jung Jutta, Saathoff Elmar, Reither Klaus, Ntinginya Elias N, Maganga Lucas, Maboko Leonard, and Hoelscher Michael
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The development and evaluation of rapid and accurate new diagnostic tools is essential to improve tuberculosis (TB) control in developing countries. In a previous study, the first release of a urine LAM-ELISA by Chemogen (Portland, USA) has been evaluated with a promising sensitivity and specificity for the diagnosis of pulmonary TB. In the present study, the now commercially available assay has been clinically assessed regarding its diagnostic value alone and in combination with clinical co-factors. Methods The test was applied to two urine samples from 291 consecutively enrolled Tanzanian patients with suspected pulmonary tuberculosis. The participants were subsequently assigned to classification groups according to microbiological, clinical and radiological findings at recruitment and during a maximum follow up period of 56 days. Results Only 35 out of 69 pulmonary TB cases -confirmed by smear microscopy and/or solid culture and/or liquid culture- showed at least one positive LAM-ELISA result (sensitivity 50.7%). The sensitivity was noticeably higher in females (66.7%) and in HIV positive participants (62.0%). The specificity amounted to 87.8% and was determined in participants with negative results in all microbiological tests and with sustained recovery under antibiotic treatment at day 56. Correlation with urinalysis revealed that proteinuria was significantly and positively associated with LAM-positivity (P = 0.026). Conclusion This commercially available generation of LAM-ELISA does not appear to be useful as an independent diagnostic test for pulmonary tuberculosis. The question whether the assay is suitable as a supplemental device in the diagnosis of HIV-associated TB, requires further investigations.
- Published
- 2009
- Full Text
- View/download PDF
25. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania
- Author
-
Berens-Riha Nicole, Maboko Leonard, Hoelscher Michael, Maduhu Ibrahim, Schunk Mirjam, Barreto Miranda Isabel, Schönfeld Mirjam, Kitua Andrew, and Löscher Thomas
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genes. Methods In samples from 86 patients with uncomplicated Plasmodium falciparum malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the pfcrt and pfmdr1 genes which are associated with CQ resistance and in pfdhfr and pfdhps, conferring SP resistance, as well in cytb which is linked to resistance to atovaquone. Results Pfcrt T76 occurs in 50% and pfmdr1 Y86 in 51.7%. Pfdhfr triple mutations coexisting with pfdhps double mutations were detected in 64.3% of the P. falciparum isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the cytb gene were not detected. Conclusion These findings of a high prevalence of mutations conferring SP resistance correspond to data of in vivo SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.
- Published
- 2007
- Full Text
- View/download PDF
26. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis.
- Author
-
Riedner G, Rusizoka M, Todd J, Maboko L, Hoelscher M, Mmbando D, Samky E, Lyamuya E, Mabey D, Grosskurth H, and Hayes R
- Published
- 2005
27. Increased HIV Incidence in Wuchereria bancrofti Microfilaria Positive Individuals in Tanzania.
- Author
-
Mnkai J, Ritter M, Maganga L, Maboko L, Olomi W, Clowes P, Minich J, Lelo AE, Kariuki D, Debrah AY, Geldmacher C, Hoelscher M, Saathoff E, Chachage M, Pfarr K, Hoerauf A, and Kroidl I
- Abstract
Background: Infections with Wuchereria bancrofti are associated with reduced immunity against concomitant infections. Indeed, our previous study described a 2.3-fold increased HIV incidence among individuals with W. bancrofti infection, as measured by the circulating filarial antigen of the adult worm. This new study aimed to retrospectively determine microfilariae status of the participants to assess if the previously described increased HIV susceptibility was associated with the presence of MF in the same cohort., Methods: CFA positive but HIV negative biobanked human blood samples ( n = 350) were analyzed for W. bancrofti MF chitinase using real time PCR., Results: The PCR provided a positive signal in 12/350 (3.4%) samples. During four years of follow-up (1109 person years (PY)), 22 study participants acquired an HIV infection. In 39 PY of W. bancrofti MF chitinase positive individuals, three new HIV infections occurred (7.8 cases per 100 PY), in contrast to 19 seroconversions in 1070 PY of W. bancrofti MF chitinase negative individuals (1.8 cases per 100 PY, p = 0.014)., Conclusions: In the subgroup of MF-producing Wb-infected individuals, the HIV incidence exceeded the previously described moderate increased risk for HIV seen in all Wb-infected individuals (regardless of MF status) compared with uninfected persons from the same area.
- Published
- 2023
- Full Text
- View/download PDF
28. Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach.
- Author
-
Mekota AM, Gillespie SH, Hoelscher M, Diacon AH, Dawson R, Churchyard G, Sanne I, Minja L, Kibiki G, Maboko L, Lakhi S, Joloba M, Alabi A, Kirenga B, McHugh TD, Grobusch MP, and Boeree MJ
- Subjects
- Humans, Africa, Northern, Capacity Building, Tanzania, Zambia, International Cooperation, Tuberculosis drug therapy, Clinical Trials as Topic
- Abstract
Introduction: The Pan-African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics (PanACEA) was designed to build tuberculosis (TB) trial capacity whilst conducting clinical trials on novel and existing agents to shorten and simplify TB treatment. PanACEA has now established a dynamic network of 11 sub-Saharan clinical trial sites and four European research institutions., Objectives: In 2011, a capacity development program, funded by the European & Developing Countries Clinical Trials Partnership (EDCTP), was launched with four objectives, aiming at strengthening collaborating TB research sites to reach the ultimate goal of becoming self-sustainable institutions: networking; training; conducting clinical trials; and infrastructure scaling-up of sites., Methods: Assessment in six sub-Saharan TB-endemic countries (Gabon, Kenya, South Africa, Tanzania, Uganda and Zambia) were performed through a structured questionnaire, site visits, discussion with the PanACEA consortium, setting of milestones and identification of priorities and followed-up with evaluations of each site. The results of this needs-based assessment was then translated into capacity development measures., Results: In the initial phase, over a four-year period (March 2011 - June 2014), the programme scaled-up six sites; conducted a monitoring training program for 11 participants; funded five MSc and four PhD students, fostering gender balance; conducted four epidemiological studies; supported sites to conduct five Phase II studies and formed a sustainable platform for TB research (panacea-tb.net)., Conclusion: Our experience of conducting TB clinical trials within the PanACEA programme environment of mentoring, networking and training has provided a sound platform for establishing future sustainable research centres. Our goal of facilitating emergent clinical TB trial sites to better initiate and lead research activities has been mostly successful., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. Perceived benefits, challenges, and recommendations for HIV research dissemination and implementation science efforts in Tanzania: Findings from the HIV/AIDS Research Forum brainstorming session.
- Author
-
Conserve DF, Saini S, Issango J, Kilale AM, Kamwela J, Maboko L, Sims W, Shirima S, Vargo J, Rawson R, Ondrus A, Ezeanolue EE, and Whembolua GL
- Abstract
Although several international and national HIV/AIDS conferences exist, there was not a national conference in Tanzania focusing on HIV/AIDS disseminating and implementation research conducted in the country and abroad. This created a missed opportunity for researchers to share their research findings with local policymakers and HIV program implementers who can influence the adoption and implementation of promising research in public health and clinical practice settings. In response, the first HIV/AIDS D&I Research Forum designed to enhance local D&I efforts for HIV research, was organized in Tanzania in 2018. This paper explores the perceived benefits of the HIV/AIDS D&I Research Forum and potential challenges of developing similar forums and recommendation for future HIV research D&I conference in Tanzania. During the second day of the Forum, which was held in September 2018 in Morogoro, Tanzania, a 1-hour structured brainstorming session was conducted with the Forum attendees (n = 50), including researchers, medical professionals, policymakers, representatives from different ministries. Transcription of the brainstorming session was analyzed to identify benefits of the Forum, perceived challenges for organizing similar HIV/AIDS research dissemination events, and recommendations for addressing the challenges. Overall, participants perceived the forum to be beneficial because it provided opportunities for strategic collaborations between researchers, policymakers, and other stakeholders and for them to discuss challenges for D&I efforts. Forum attendees also identified several potential challenges for future D&I research forums such as the abstract requirement which may deter non-researchers, costs, meeting frequencies, and lack of funding and coordination between organizations involved in D&I research efforts. To address these concerns, a recommendation was made to host a biennial national conference in order to allow more time for ethical review and feedback that can enhance contribution of the project to D&I efforts and to raise funds. The benefits identified for the Forum highlight the importance of organizing similar D&I meetings for HIV-related research at the national level in Tanzania. However, the potential challenges discussed need to be addressed in order to develop a sustainable national D&I research conference by incorporating recommendations that forum attendees proposed., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2022 Conserve et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2022
- Full Text
- View/download PDF
30. Development, Implementation, and Scale Up of the National Furaha Yangu Campaign to Promote HIV Test and Treat Services Uptake Among Men in Tanzania.
- Author
-
Conserve DF, Msofe J, Issango J, Tureski K, McCarthy P, Rwezahura P, Maboko L, Lwakatare M, Ndugulile F, Kamwela J, Sims W, Ahonkhai AA, and Whembolua GL
- Subjects
- Female, Focus Groups, Humans, Male, Qualitative Research, Tanzania, HIV Infections diagnosis, HIV Infections drug therapy, HIV Testing
- Abstract
Evidence has demonstrated that immediate HIV treatment initiation upon a positive HIV test, referred to as Test and Treat, can help people living with HIV live longer, healthier lives and prevent HIV transmission. Although Tanzania adopted the evidence-based Test and Treat strategy since 2016, men were not being adequately reached for HIV services. A national campaign was launched to promote the new HIV services with a focus on men. To inform the development and implementation of the campaign, we conducted formative audience insights-gathering (AIG) sessions to assess facilitators and barriers to accessing HIV Test and Treat services and inform the concepts and materials for the campaign. Qualitative AIG interviews and focus group discussions were conducted with 54 people who were unaware or aware of their HIV status and currently or not currently on treatment, as well as health workers. Facilitators and barriers included a fear of testing positive, the desire to belong , control their narratives, and reinvent themselves to achieve their dreams and live a happy life. The campaign played off a My Happiness! creative concept to position antiretroviral therapy (ART) as a solution to fears around what life would be like after a positive HIV diagnosis. The development and implementation of the campaign were informed by the AIG sessions and national stakeholders, leading to strong partners' buy-in that supported the scale-up of the ongoing campaign from 12 to 26 regions via the collaborative efforts of government, donors, and implementing partners.
- Published
- 2022
- Full Text
- View/download PDF
31. HPV Type Distribution in HIV Positive and Negative Women With or Without Cervical Dysplasia or Cancer in East Africa.
- Author
-
Mcharo R, Lennemann T, France J, Torres L, Garí M, Mbuya W, Mwalongo W, Mahenge A, Bauer A, Mnkai J, Glasmeyer L, Judick M, Paul M, Schroeder N, Msomba B, Sembo M, Chiwerengo N, Hoelscher M, Geisenberger O, Lelle RJ, Saathoff E, Maboko L, Chachage M, Kroidl A, and Geldmacher C
- Abstract
Background: Women living with HIV in sub-Saharan Africa are at increased risk to develop cervical cancer (CC), which is caused by persistent infection with 13 oncogenic human papilloma viruses (HR-HPVs). It is important to accurately identify and target HIV-positive women at highest risk to develop CC for early therapeutic intervention., Methods: A total of 2,134 HIV+ and HIV- women from South-West Tanzania were prospectively screened for cervical cancer and precancerous lesions. Women with cervical cancer (n=236), high- and low-grade squamous intraepithelial lesions (HSIL: n=68, LSIL: n=74), and without lesion (n=426) underwent high-resolution HPV genotyping., Results: Eighty percent of women who were diagnosed with HSIL or LSIL were living with HIV. Any lesion, young age, HIV status, and depleted CD4 T cell counts were independent risk factors for HPV infections, which were predominantly caused by HR-HPV types. While multiple HR-HPV type infections were predominant in HIV+ women with HSIL, single-type infections predominated in HIV+ CC cases (p=0.0006). HPV16, 18, and 45 accounted for 85% (68/80) and 75% (82/110) of HIV+ and HIV- CC cases, respectively. Of note, HPV35, the most frequent HPV type in HSIL-positive women living with HIV, was rarely detected as a single-type infection in HSIL and cancer cases., Conclusion: HPV16, 18, and 45 should receive special attention for molecular diagnostic algorithms during CC prevention programs for HIV+ women from sub-Saharan Africa. HPV35 may have a high potential to induce HSIL in women living with HIV, but less potential to cause cervical cancer in single-type infections., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Mcharo, Lennemann, France, Torres, Garí, Mbuya, Mwalongo, Mahenge, Bauer, Mnkai, Glasmeyer, Judick, Paul, Schroeder, Msomba, Sembo, Chiwerengo, Hoelscher, Geisenberger, Lelle, Saathoff, Maboko, Chachage, Kroidl and Geldmacher.)
- Published
- 2021
- Full Text
- View/download PDF
32. Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living With HIV.
- Author
-
Mbuya W, Held K, Mcharo RD, Haule A, Mhizde J, Mnkai J, Mahenge A, Mwakatima M, Sembo M, Mwalongo W, Agrea P, Hoelscher M, Maboko L, Saathoff E, Geisenberger O, Rwegoshora F, Torres L, Koup RA, Kroidl A, Chachage M, and Geldmacher C
- Subjects
- Adult, Female, Humans, Middle Aged, Uterine Cervical Neoplasms immunology, Uterine Cervical Neoplasms virology, Alphapapillomavirus immunology, Coinfection immunology, HIV Infections immunology, Oncogene Proteins, Viral immunology, Papillomavirus Infections immunology, T-Lymphocytes immunology
- Abstract
Background: Cervical cancer - caused by persistent High Risk Human Papilloma Virus (HR HPV) infections - is the second most common cancer affecting women globally. HIV infection increases the risk for HPV persistence, associated disease progression and malignant cell transformation. We therefore hypothesized that this risk increase is directly linked to HIV infection associated dysfunction or depletion of HPV-oncoprotein-specific T-cell responses., Methods: The 2H study specifically included HIV+ and HIV- women with and without cervical lesions and cancer to analyze HPV oncogene-specific T cell responses in relation to HPV infection, cervical lesion status and HIV status. Oncoprotein E6 and E7 specific T-cell responses were quantified for the most relevant types HPV16, 18 and 45 and control antigens (CMV-pp65) and M.tb -PPD in 373 women, using fresh peripheral blood mononuclear cells in an IFN-γ release ELISpot assay., Results: Overall, systemic E6- and E7-oncoprotein-specific T-cell responses were infrequent and of low magnitude, when compared to CMV-pp65 and M.tb -PPD (p < 0.001 for all HR HPV types). Within HIV negative women infected with either HPV16, 18 or 45, HPV16 infected women had lowest frequency of autologous-type-E6/E7-specific T-cell responses (33%, 16/49), as compared to HPV18 (46% (6/13), p = 0.516) and HPV45 (69% (9/13), p = 0.026) infected women. Prevalent HPV18 and 45, but not HPV16 infections were linked to detectable oncoprotein-specific T-cell responses, and for these infections, HIV infection significantly diminished T-cell responses targeting the autologous infecting genotype. Within women living with HIV, low CD4 T-cell counts, detectable HIV viremia as well as cancerous and precancerous lesions were significantly associated with depletion of HPV oncoprotein-specific T-cell responses., Discussion: Depletion of HPV-oncoprotein-specific T-cell responses likely contributes to the increased risk for HR HPV persistence and associated cancerogenesis in women living with HIV. The low inherent immunogenicity of HPV16 oncoproteins may contribute to the exceptional potential for cancerogenesis associated with HPV16 infections., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Mbuya, Held, Mcharo, Haule, Mhizde, Mnkai, Mahenge, Mwakatima, Sembo, Mwalongo, Agrea, Hoelscher, Maboko, Saathoff, Geisenberger, Rwegoshora, Torres, Koup, Kroidl, Chachage and Geldmacher.)
- Published
- 2021
- Full Text
- View/download PDF
33. Wuchereria bancrofti infection is linked to systemic activation of CD4 and CD8 T cells.
- Author
-
Kroidl I, Chachage M, Mnkai J, Nsojo A, Berninghoff M, Verweij JJ, Maganga L, Ntinginya NE, Maboko L, Clowes P, Hoelscher M, Saathoff E, and Geldmacher C
- Subjects
- Adult, Aged, Aged, 80 and over, Animals, Antigens, CD analysis, CD4-Positive T-Lymphocytes chemistry, CD8-Positive T-Lymphocytes chemistry, Elephantiasis, Filarial immunology, Female, Flow Cytometry, HLA-DR Antigens analysis, Humans, Male, Middle Aged, Prospective Studies, T-Lymphocyte Subsets chemistry, Young Adult, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Elephantiasis, Filarial pathology, Lymphocyte Activation, T-Lymphocyte Subsets immunology, Wuchereria bancrofti immunology
- Abstract
Background: Susceptibility to HIV has been linked to systemic CD4+ T cell activation in cohorts of seronegative individuals with high HIV-exposure risk. We recently described an increased risk of HIV transmission in individuals infected with Wuchereria bancrofti, the causative agent for lymphatic filariasis, in a prospective cohort study. However, the reason for this phenomenon needs further investigation., Methodology/principal Findings: Two-hundred and thirty-five HIV negative adults were tested using Trop Bio ELISA for detection of W. bancrofti infection and Kato Katz urine filtration and stool based RT-PCR for detection of soil transmitted helminths and schistosomiasis. FACS analysis of the fresh peripheral whole blood was used to measure T cell activation markers (HLA-DR, CD38), differentiation markers (CD45, CD27), markers for regulatory T cells (FoxP3, CD25) and the HIV entry receptor CCR5. Frequencies of activated HLA-DRpos CD4 T cells were significantly increased in subjects with W. bancrofti infection (n = 33 median: 10.71%) compared to subjects without any helminth infection (n = 42, median 6.97%, p = 0.011) or those with other helminths (Schistosoma haematobium, S. mansoni, Trichuris trichiura, Ascaris lumbricoides, hookworm) (n = 151, median 7.38%, p = 0.009). Similarly, a significant increase in HLA-DRposCD38pos CD4 T cells and effector memory cells CD4 T cells (CD45ROposCD27neg) was observed in filarial infected participants. Multivariable analyses further confirmed a link between W. bancrofti infection and systemic activation of CD4 T cells independent of age, fever, gender or other helminth infections., Conclusions/significance: W. bancrofti infection is linked to systemic CD4 T cell activation, which may contribute to the increased susceptibility of W. bancrofti infected individuals to HIV infection., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
34. Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.
- Author
-
Nadai Y, Held K, Joseph S, Ahmed MIM, Hoffmann VS, Peterhoff D, Missanga M, Bauer A, Joachim A, Reimer U, Zerweck J, McCormack S, Cope AV, Tatoud R, Shattock RJ, Robb ML, Sandstroem EG, Hoelscher M, Maboko L, Bakari M, Kroidl A, Wagner R, Weber J, Pollakis G, and Geldmacher C
- Subjects
- Adolescent, Adult, Amino Acid Motifs, Amino Acid Sequence, Antibody Specificity immunology, Antigens, Viral chemistry, Epitope Mapping, Epitopes chemistry, Epitopes immunology, Female, HIV classification, HIV genetics, HIV Infections prevention & control, HIV Infections virology, Humans, Immunization Schedule, Immunization, Secondary, Male, Models, Molecular, Phylogeny, Protein Binding, Protein Conformation, Structure-Activity Relationship, Vaccination, Young Adult, env Gene Products, Human Immunodeficiency Virus chemistry, env Gene Products, Human Immunodeficiency Virus genetics, AIDS Vaccines immunology, Antigens, Viral immunology, HIV immunology, HIV Antibodies immunology, HIV Infections immunology, Immunoglobulin G immunology, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Background: A better understanding of the parameters influencing vaccine-induced IgG recognition of individual antigenic regions and their variants within the HIV Envelope protein (Env) can help to improve design of preventive HIV vaccines. Methods: Env-specific IgG responses were mapped in samples of the UKHVC003 Standard Group (UK003SG, n = 11 from UK) and TaMoVac01 (TMV01, n = 17 from Tanzania) HIV vaccine trials. Both trials consisted of three immunizations with DNA, followed by two boosts with recombinant Modified Vaccinia Virus Ankara (MVA), either mediating secretion of gp120 (UK003SG) or the presentation of cell membrane bound gp150 envelopes (TMV01) from infected cells, and an additional two boosts with 5 μg of CN54gp140 protein adjuvanted with glucopyranosyl lipid adjuvant (GLA). Env immunogen sequences in UK003SG were solely based on the clade C isolate CN54, whereas in TMV01 these were based on clades A, C, B, and CRF01AE. The peptide microarray included 8 globally representative Env sequences, CN54gp140 and the MVA-encoded Env immunogens from both trials, as well as additional peptide variants for hot spots of immune recognition. Results: After the second MVA boost, UK003SG vaccinees almost exclusively targeted linear, non-glycosylated antigenic regions located in the inter-gp120 interface. In contrast, TMV01 recipients most strongly targeted the V2 region and an immunodominant region in gp41. The V3 region was frequently targeted in both trials, with a higher recognition magnitude for diverse antigenic variants observed in the UK003SG ( p < 0.0001). After boosting with CN54gp140/GLA, the overall response magnitude increased with a more comparable recognition pattern of antigenic regions and variants between the two trials. Recognition of most immunodominant regions within gp120 remained significantly stronger in UK003SG, whereas V2-region recognition was not boosted in either group. Conclusions: IgG recognition of linear antigenic Env regions differed between the two trials particularly after the second MVA boost. Structural features of the MVA-encoded immunogens, such as secreted, monomeric gp120 vs. membrane-anchored, functional gp150, and differences in prime-boost immunogen sequence variability most probably contributed to these differences. Prime-boosting with multivalent Env immunogens during TMV01 did not improve variant cross-recognition of immunodominant peptide variants in the V3 region.
- Published
- 2019
- Full Text
- View/download PDF
35. Accuracy and Operational Characteristics of Xpert Human Immunodeficiency Virus Point-of-Care Testing at Birth and Until Week 6 in Human Immunodeficiency Virus-exposed Neonates in Tanzania.
- Author
-
Sabi I, Mahiga H, Mgaya J, Geisenberger O, Kastner S, Olomi W, Saathoff E, Njovu L, Lueer C, France J, Maboko L, Ntinginya NE, Hoelscher M, and Kroidl A
- Subjects
- Adult, Early Diagnosis, Female, Humans, Infant, Newborn, Male, Prospective Studies, Sensitivity and Specificity, Tanzania, Young Adult, Diagnostic Tests, Routine methods, HIV Infections diagnosis, Molecular Diagnostic Techniques methods, Point-of-Care Testing
- Abstract
Background: Point-of-care (PoC) systems for early infant diagnosis (EID) may improve timely infant human immunodeficiency virus (HIV) management. Experiences within African public health settings are limited., Methods: We evaluated the accuracy and operational feasibility of the Xpert HIV-1 Qual for PoC-EID testing, using fresh blood and dried blood spots (DBS) samples at obstetric health facilities in Tanzania at birth and at postpartum weeks 1, 2, 3, and 6 in HIV-exposed infants. Test results were confirmed using TaqMan DBS HIV-deoxyribonucleic acid and/or plasma HIV-ribonucleic acid (RNA) testing., Results: At week 6, 15 (2.5%) out of 614 infants were diagnosed with HIV; 10 (66.7%) of them at birth (median HIV-RNA 4570 copies/mL). At birth, the Xpert-PoC and Xpert-DBS were 100% sensitive (95% confidence intervals: PoC, 69.2-100%; DBS, 66.4-100%) and 100% specific (PoC, 92.1-100%; DBS, 88.4-100%). By week 3, 5 infants with intra/postpartum HIV-infection (median HIV-RNA 1 160 000 copies/mL) were all correctly diagnosed by Xpert. In 2 cases, Xpert-PoC testing correctly identified HIV-infection when DBS tests (Xpert and TaqMan) were negative, suggesting a greater sensitivity. In 2 infants with confirmed HIV at birth, all tests were negative at week 6, possibly because of viral suppression under nevirapine prophylaxis. Problems were reported in 183/2736 (6.7%) of Xpert-PoC tests, mostly related to power cuts (57.9%)., Conclusions: We demonstrated excellent Xpert HIV-1 Qual performance and good operational feasibility for PoC-EID testing at obstetric health facilities. Week 6 sensitivity issues were possibly related to nevirapine prophylaxis, supporting additional birth PoC-EID testing to avoid underdiagnosis., Clinical Trials Registration: NCT02545296.
- Published
- 2019
- Full Text
- View/download PDF
36. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
- Author
-
Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, and Lyamuya E
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines adverse effects, AIDS Vaccines genetics, Administration, Cutaneous, Adult, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Electroporation, Female, Glucosides immunology, HIV Antibodies blood, HIV Antibodies immunology, HIV-1 immunology, Healthy Volunteers, Humans, Immunization, Secondary methods, Lipid A immunology, Male, Mozambique, Tanzania, Vaccination methods, Vaccines, DNA administration & dosage, Vaccines, DNA adverse effects, Vaccines, DNA genetics, Vaccinia virus immunology, Viral Vaccines administration & dosage, Viral Vaccines adverse effects, Viral Vaccines genetics, Young Adult, env Gene Products, Human Immunodeficiency Virus genetics, env Gene Products, Human Immunodeficiency Virus immunology, AIDS Vaccines immunology, HIV Infections prevention & control, Immunogenicity, Vaccine, Vaccines, DNA immunology, Viral Vaccines immunology
- Abstract
Background: We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein adjuvanted with Glucopyranosyl Lipid A (GLA-AF) in volunteers from Tanzania and Mozambique., Methods: Healthy HIV-uninfected adults (N = 191) were randomized twice; first to one of three HIV-DNA intradermal priming regimens by needle-free ZetaJet device at weeks 0, 4 and 12 (Group I: 2x0.1mL [3mg/mL], Group II: 2x0.1mL [3mg/mL] plus EP, Group III: 1x0.1mL [6mg/mL] plus EP). Second the same volunteers received 108 pfu HIV-MVA twice, alone or combined with CN54rgp140/GLA-AF, intramuscularly by syringe, 16 weeks apart. Additionally, 20 volunteers received saline placebo., Results: Vaccinations and electroporation did not raise safety concerns. After the last vaccination, the overall IFN-γ ELISpot response rate to either Gag or Env was 97%. Intradermal electroporation significantly increased ELISpot response rates to HIV-DNA-specific Gag (66% group I vs. 86% group II, p = 0.026), but not to the HIV-MVA vaccine-specific Gag or Env peptide pools nor the magnitude of responses. Co-administration of rgp140/GLA-AF with HIV-MVA did not impact the frequency of binding antibody responses against subtype B gp160, C gp140 or E gp120 antigens (95%, 99%, 79%, respectively), but significantly enhanced the magnitude against subtype B gp160 (2700 versus 300, p<0.001) and subtype C gp140 (24300 versus 2700, p<0.001) Env protein. At relatively low titers, neutralizing antibody responses using the TZM-bl assay were more frequent in vaccinees given adjuvanted protein boost., Conclusion: Intradermal electroporation increased DNA-induced Gag response rates but did not show an impact on Env-specific responses nor on the magnitude of responses. Co-administration of HIV-MVA with rgp140/GLA-AF significantly enhanced antibody responses., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
37. Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants.
- Author
-
Froeschl G, Saathoff E, Kroidl I, Berens-Riha N, Clowes P, Maboko L, Assisya W, Mwalongo W, Gerhardt M, Ntinginya EN, and Hoelscher M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Drug Combinations, Female, Humans, Infant, Infant, Newborn, Longitudinal Studies, Malaria, Falciparum prevention & control, Male, Middle Aged, Prevalence, Tanzania epidemiology, Young Adult, Antimalarials therapeutic use, Artemisinins therapeutic use, Malaria, Falciparum epidemiology
- Abstract
Background: A marked decline in malaria morbidity and mortality has been reported after the introduction of artemisinin-based combination therapy (ACT) in high malaria prevalence countries in Africa. Data on the impact of ACT and on the prevalence of malaria has so far been scarce for Southwest Tanzania., Methods: Between 2005 and 2011, a large general population cohort in the Mbeya Region in the south-west of Tanzania has been surveyed within the EMINI-study (Evaluation and Monitoring of the Impact of New Interventions). Participants were examined once per year, including rapid diagnostic testing for malaria. ACT was introduced in the region according to national guidelines in the time period 2006/2007, replacing sulfadoxine/pyrimethamine as first-line therapy. In four study sites, 6773 individuals who participated in the first two of three consecutive survey visits in the period from 2006 to 2009 were included in this analysis. The prevalence of Plasmodium infection prior to and after the introduction of ACT was compared by logistic regression, with consideration of climatic variability, age, sex, socio-economic status and bed net use as potential confounders., Results: A significant reduction over time in the prevalence of Plasmodium falciparum infection from 2.5 to 0.3% was shown across the four study sites. The decline was not explained by other factors included in the analysis, therefore, the decline over time most likely reflects the impact of introduction of ACT in the study area., Conclusions: The longitudinal study showed a significant and relevant decline in the prevalence of P. falciparum infection after introduction of ACT, which could not be explained by potential confounders. The data suggests that artemisinin-based combinations are not only an effective instrument for reduction of immediate morbidity and mortality, but also for reduction of transmission rates.
- Published
- 2018
- Full Text
- View/download PDF
38. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
- Author
-
Ake JA, Schuetz A, Pegu P, Wieczorek L, Eller MA, Kibuuka H, Sawe F, Maboko L, Polonis V, Karasavva N, Weiner D, Sekiziyivu A, Kosgei J, Missanga M, Kroidl A, Mann P, Ratto-Kim S, Anne Eller L, Earl P, Moss B, Dorsey-Spitz J, Milazzo M, Laissa Ouedraogo G, Rizvi F, Yan J, Khan AS, Peel S, Sardesai NY, Michael NL, Ngauy V, Marovich M, and Robb ML
- Subjects
- Adult, Africa, Eastern, Double-Blind Method, Electroporation, Female, Humans, Male, Middle Aged, United States, Vaccination, AIDS Vaccines administration & dosage, AIDS Vaccines immunology, HIV Antibodies blood, HIV Infections prevention & control, Immunity, Cellular drug effects, Vaccinia virus immunology
- Abstract
Background: We report the first-in-human safety and immunogenicity evaluation of PENNVAX-G DNA/modified vaccinia Ankara-Chiang Mai double recombinant (MVA-CMDR) prime-boost human immuonodeficiency virus (HIV) vaccine, with intramuscular DNA delivery by either Biojector 2000 needle-free injection system (Biojector) or CELLECTRA electroporation device., Methods: Healthy, HIV-uninfected adults were randomized to receive 4 mg of PENNVAX-G DNA delivered intramuscularly by Biojector or electroporation at baseline and week 4 followed by intramuscular injection of 108 plaque forming units of MVA-CMDR at weeks 12 and 24. The open-label part A was conducted in the United States, followed by a double-blind, placebo-controlled part B in East Africa. Solicited and unsolicited adverse events were recorded, and immune responses were measured., Results: Eighty-eight of 100 enrolled participants completed all study injections, which were generally safe and well tolerated, with more immediate, but transient, pain in the electroporation group. Cellular responses were observed in 57% of vaccine recipients tested and were CD4 predominant. High rates of binding antibody responses to CRF01_AE antigens, including gp70 V1V2 scaffold, were observed. Neutralizing antibodies were detected in a peripheral blood mononuclear cell assay, and moderate antibody-dependent, cell-mediated cytotoxicity activity was demonstrated., Discussion: The PVG/MVA-CMDR HIV-1 vaccine regimen is safe and immunogenic. Substantial differences in safety or immunogenicity between modes of DNA delivery were not observed., Clinical Trials Registration: NCT01260727., (Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.)
- Published
- 2017
- Full Text
- View/download PDF
39. Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
- Author
-
Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Karim SA, Karim QA, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, and Williamson C
- Abstract
[This corrects the article DOI: 10.1371/journal.ppat.1005742.].
- Published
- 2017
- Full Text
- View/download PDF
40. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
- Author
-
Bauer A, Podola L, Mann P, Missanga M, Haule A, Sudi L, Nilsson C, Kaluwa B, Lueer C, Mwakatima M, Munseri PJ, Maboko L, Robb ML, Tovanabutra S, Kijak G, Marovich M, McCormack S, Joseph S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Bakari M, Kroidl A, and Geldmacher C
- Subjects
- AIDS Vaccines administration & dosage, Drug Carriers, Healthy Volunteers, Humans, Interferon-gamma metabolism, Interleukin-2 metabolism, T-Lymphocyte Subsets immunology, Tanzania, Tumor Necrosis Factor-alpha metabolism, Vaccines, DNA administration & dosage, Vaccines, Subunit administration & dosage, Vaccines, Subunit immunology, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Vaccinia virus genetics, AIDS Vaccines immunology, HIV-1 immunology, T-Lymphocytes immunology, Vaccination methods, Vaccines, DNA immunology, gag Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Prime-boost vaccination strategies against HIV-1 often include multiple variants for a given immunogen for better coverage of the extensive viral diversity. To study the immunologic effects of this approach, we characterized breadth, phenotype, function, and specificity of Gag-specific T cells induced by a DNA-prime modified vaccinia virus Ankara (MVA)-boost vaccination strategy, which uses mismatched Gag immunogens in the TamoVac 01 phase IIa trial. Healthy Tanzanian volunteers received three injections of the DNA-SMI vaccine encoding a subtype B and AB-recombinant Gag
p37 and two vaccinations with MVA-CMDR encoding subtype A Gagp55 Gag-specific T-cell responses were studied in 42 vaccinees using fresh peripheral blood mononuclear cells. After the first MVA-CMDR boost, vaccine-induced gamma interferon-positive (IFN-γ+ ) Gag-specific T-cell responses were dominated by CD4+ T cells ( P < 0.001 compared to CD8+ T cells) that coexpressed interleukin-2 (IL-2) (66.4%) and/or tumor necrosis factor alpha (TNF-α) (63.7%). A median of 3 antigenic regions were targeted with a higher-magnitude median response to Gagp24 regions, more conserved between prime and boost, compared to those of regions within Gagp15 (not primed) and Gagp17 (less conserved; P < 0.0001 for both). Four regions within Gagp24 each were targeted by 45% to 74% of vaccinees upon restimulation with DNA-SMI-Gag matched peptides. The response rate to individual antigenic regions correlated with the sequence homology between the MVA- and DNA Gag-encoded immunogens ( P = 0.04, r2 = 0.47). In summary, after the first MVA-CMDR boost, the sequence-mismatched DNA-prime MVA-boost vaccine strategy induced a Gag-specific T-cell response that was dominated by polyfunctional CD4+ T cells and that targeted multiple antigenic regions within the conserved Gagp24 protein. IMPORTANCE Genetic diversity is a major challenge for the design of vaccines against variable viruses. While including multiple variants for a given immunogen in prime-boost vaccination strategies is one approach that aims to improve coverage for global virus variants, the immunologic consequences of this strategy have been poorly defined so far. It is unclear whether inclusion of multiple variants in prime-boost vaccination strategies improves recognition of variant viruses by T cells and by which mechanisms this would be achieved, either by improved cross-recognition of multiple variants for a given antigenic region or through preferential targeting of antigenic regions more conserved between prime and boost. Engineering vaccines to induce adaptive immune responses that preferentially target conserved antigenic regions of viral vulnerability might facilitate better immune control after preventive and therapeutic vaccination for HIV and for other variable viruses., (Copyright © 2017 American Society for Microbiology.)- Published
- 2017
- Full Text
- View/download PDF
41. Linkage into care among newly diagnosed HIV-positive individuals tested through outreach and facility-based HIV testing models in Mbeya, Tanzania: a prospective mixed-method cohort study.
- Author
-
Sanga ES, Lerebo W, Mushi AK, Clowes P, Olomi W, Maboko L, and Zarowsky C
- Subjects
- Adult, CD4 Lymphocyte Count, Community Health Services, Female, HIV Infections drug therapy, Humans, Kaplan-Meier Estimate, Male, Mass Screening, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Prospective Studies, Rural Population, Serologic Tests, Surveys and Questionnaires, Tanzania, HIV Infections diagnosis, Health Services Accessibility statistics & numerical data, Mobile Health Units statistics & numerical data, Time-to-Treatment statistics & numerical data
- Abstract
Objective: Linkage to care is the bridge between HIV testing and HIV treatment, care and support. In Tanzania, mobile testing aims to address historically low testing rates. Linkage to care was reported at 14% in 2009 and 28% in 2014. The study compares linkage to care of HIV-positive individuals tested at mobile/outreach versus public health facility-based services within the first 6 months of HIV diagnosis., Setting: Rural communities in four districts of Mbeya Region, Tanzania., Participants: A total of 1012 newly diagnosed HIV-positive adults from 16 testing facilities were enrolled into a two-armed cohort and followed for 6 months between August 2014 and July 2015. 840 (83%) participants completed the study., Main Outcome Measures: We compared the ratios and time variance in linkage to care using the Kaplan-Meier estimator and Log rank tests. Cox proportional hazards regression models to evaluate factors associated with time variance in linkage., Results: At the end of 6 months, 78% of all respondents had linked into care, with differences across testing models. 84% (CI 81% to 87%, n=512) of individuals tested at facility-based site were linked to care compared to 69% (CI 65% to 74%, n=281) of individuals tested at mobile/outreach. The median time to linkage was 1 day (IQR: 1-7.5) for facility-based site and 6 days (IQR: 3-11) for mobile/outreach sites. Participants tested at facility-based site were 78% more likely to link than those tested at mobile/outreach when other variables were controlled (AHR=1.78; 95% CI 1.52 to 2.07). HIV status disclosure to family/relatives was significantly associated with linkage to care (AHR=2.64; 95% CI 2.05 to 3.39)., Conclusions: Linkage to care after testing HIV positive in rural Tanzania has increased markedly since 2014, across testing models. Individuals tested at facility-based sites linked in significantly higher proportion and modestly sooner than mobile/outreach tested individuals. Mobile/outreach testing models bring HIV testing services closer to people. Strategies to improve linkage from mobile/outreach models are needed., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)
- Published
- 2017
- Full Text
- View/download PDF
42. Trichuris trichiura infection and its relation to environmental factors in Mbeya region, Tanzania: A cross-sectional, population-based study.
- Author
-
Manz KM, Clowes P, Kroidl I, Kowuor DO, Geldmacher C, Ntinginya NE, Maboko L, Hoelscher M, and Saathoff E
- Subjects
- Adolescent, Animals, Cross-Sectional Studies, Female, Humans, Male, Risk Factors, Tanzania epidemiology, Trichuriasis epidemiology, Trichuris pathogenicity
- Abstract
Background: The intestinal nematode Trichuris trichiura is among the most common causes of human infectious disease worldwide. As for other soil-transmitted nematodes, its reproductive success and thus prevalence and intensity of infection in a given area strongly depend on environmental conditions. Characterization of the influence of environmental factors can therefore aid to identify infection hot spots for targeted mass treatment., Methodology: We analyzed data from a cross-sectional survey including 6234 participants from nine distinct study sites in Mbeya region, Tanzania. A geographic information system was used to combine remotely sensed and individual data, which were analyzed using uni- and multivariable Poisson regression. Household clustering was accounted for and when necessary, fractional polynomials were used to capture non-linear relationships between T. trichiura infection prevalence and environmental variables., Principal Findings: T. trichiura infection was restricted to the Kyela site, close to Lake Nyasa with only very few cases in the other eight sites. The prevalence of T. trichiura infection in Kyela was 26.6% (95% confidence interval (CI) 23.9 to 29.6%). Multivariable models revealed a positive association of infection with denser vegetation (prevalence ratio (PR) per 0.1 EVI units = 2.12, CI 1.28 to 3.50) and inverse associations with rainfall (PR per 100 mm = 0.54, CI 0.44 to 0.67) and elevation (PR per meter = 0.89, CI 0.86 to 0.93) while adjusting for age and previous worm treatment. Slope of the terrain was modelled non-linearly and also showed a positive association with T. trichiura infection (p-value p<0.001)., Conclusion/significance: Higher prevalences of T. trichiura infection were only found in Kyela, a study site characterized by denser vegetation, high rainfall, low elevation and flat terrain. But even within this site, we found significant influences of vegetation density, rainfall, elevation and slope on T. trichiura infection. The inverse association of rainfall with infection in Kyela is likely due to the fact, that rainfall in this site is beyond the optimum conditions for egg development. Our findings demonstrate that use of remotely sensed environmental data can aid to predict high-risk areas for targeted helminth control.
- Published
- 2017
- Full Text
- View/download PDF
43. HIV-1 Genetic Diversity Among Incident Infections in Mbeya, Tanzania.
- Author
-
Billings E, Sanders-Buell E, Bose M, Kijak GH, Bradfield A, Crossler J, Arroyo MA, Maboko L, Hoffmann O, Geis S, Birx DL, Kim JH, Michael NL, Robb ML, Hoelscher M, and Tovanabutra S
- Subjects
- Adolescent, Adult, Africa, Female, Genome, Viral, Genotype, HIV-1 isolation & purification, Humans, Male, Middle Aged, Molecular Epidemiology, Prospective Studies, Recombination, Genetic, Retrospective Studies, Sequence Analysis, DNA, Tanzania epidemiology, Young Adult, Genetic Variation, HIV Infections epidemiology, HIV Infections virology, HIV-1 classification, HIV-1 genetics
- Abstract
In preparation for vaccine trials, HIV-1 genetic diversity was surveyed between 2002 and 2006 through the Cohort Development study in the form of a retrospective and prospective observational study in and around the town of Mbeya in Tanzania's Southwest Highlands. This study describes the molecular epidemiology of HIV-1 strains obtained from 97 out of 106 incident HIV-1 infections identified in three subpopulations of participants (one rural, two urban) from the Mbeya area. Near full-genome or half-genome sequencing showed a subtype distribution of 40% C, 17% A1, 1% D, and 42% inter-subtype recombinants. Compared to viral subtyping results previously obtained from the retrospective phase of this study, the overall proportion of incident viral strains did not change greatly during the study course, suggesting maturity of the epidemic. A comparison to a current Phase I-II vaccine being tested in Africa shows ∼17% amino acid sequence difference between the gp120 of the vaccine and subtype C incident strains. Phylogenetic and recombinant breakpoint analysis of the incident strains revealed the emergence of CRF41_CD and many unique recombinants, as well as the presence of six local transmission networks most of which were confined to the rural subpopulation. In the context of vaccine cohort selection, these results suggest distinct infection transmission dynamics within these three geographically close subpopulations. The diversity and genetic sequences of the HIV-1 strains obtained during this study will greatly contribute to the planning, immunogen selection, and analysis of vaccine-induced immune responses observed during HIV-1 vaccine trials in Tanzania and neighboring countries.
- Published
- 2017
- Full Text
- View/download PDF
44. Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort study.
- Author
-
Kroidl I, Saathoff E, Maganga L, Makunde WH, Hoerauf A, Geldmacher C, Clowes P, Maboko L, and Hoelscher M
- Subjects
- Adolescent, Adult, Animals, Circumcision, Male, Enzyme-Linked Immunosorbent Assay, Female, Humans, Incidence, Male, Marital Status, Middle Aged, Prevalence, Prospective Studies, Risk Assessment, Risk Factors, Sampling Studies, Sexual Partners, Tanzania epidemiology, Wuchereria bancrofti isolation & purification, Antigens, Helminth blood, Elephantiasis, Filarial epidemiology, Elephantiasis, Filarial immunology, Endemic Diseases statistics & numerical data, HIV Infections epidemiology, HIV Infections immunology, Wuchereria bancrofti immunology
- Abstract
Background: The past decades have seen an ongoing controversial debate about whether the immune activation induced by helminths has an effect on the susceptibility of individuals to HIV. In view of this, we assessed the effect of lymphatic filariasis, a chronic helminth disease elicited by Wuchereria bancrofti, on HIV incidence in southwest Tanzania., Methods: In this population-based cohort study, we enrolled a geographically stratified randomly chosen sample of about 10% of the households in nine distinct sites in southwest Tanzania. All household members present were followed up and tested for HIV and circulating filarial antigen, an indicator of W bancrofti adult worm burden. Our main outcome of interest was HIV incidence in participants with or without lymphatic filariasis., Findings: Between May 29, 2006, and June 16, 2011, we enrolled 4283 households with roughly 18 000 participants. Of these, 2699 individuals from Kyela district participated in at least one round of the EMINI study. In the 1055 initially HIV-negative adolescents and adults with clearly defined lymphatic filariasis status, 32 new HIV infections were observed in 2626 person-years. HIV incidence in lymphatic filariasis-positive participants (1·91 cases per 100 person-years) was significantly higher than the incidence in lymphatic filariasis-negative participants (0·80 cases per 100 person-years). The age-adjusted and sex-adjusted incidence rate ratio was 2·17 (95% CI 1·08-4·37, p=0·0300). Lymphatic filariasis status remained an independent and significantly relevant risk factor for HIV infection when controlled for other known risk factors such as sexual behaviour and socioeconomic factors., Interpretation: To our knowledge, this is the first prospective study demonstrating a significantly increased risk of acquiring HIV for lymphatic filariasis-infected individuals. Immunological studies and interventional treatment studies that eliminate the adult worms and not only the microfilariae are needed to follow up on the results presented., Funding: European Union as part of EuropAid; German Federal Ministry of Education and Research; German Center for Infection Research., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
45. CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo.
- Author
-
Chachage M, Pollakis G, Kuffour EO, Haase K, Bauer A, Nadai Y, Podola L, Clowes P, Schiemann M, Henkel L, Hoffmann D, Joseph S, Bhuju S, Maboko L, Sarfo FS, Eberhardt K, Hoelscher M, Feldt T, Saathoff E, and Geldmacher C
- Subjects
- CD4-Positive T-Lymphocytes chemistry, DNA, Viral analysis, DNA, Viral genetics, HIV classification, HIV genetics, Humans, Ki-67 Antigen analysis, Phylogeny, Sequence Analysis, DNA, T-Lymphocyte Subsets chemistry, env Gene Products, Human Immunodeficiency Virus genetics, CD4-Positive T-Lymphocytes virology, Forkhead Transcription Factors analysis, HIV isolation & purification, HIV Infections virology, Interleukin-2 Receptor alpha Subunit analysis, Receptors, CCR5 analysis, T-Lymphocyte Subsets virology
- Abstract
Unlabelled: Interleukin 2 (IL-2) signaling through the IL-2 receptor alpha chain (CD25) facilitates HIV replication in vitro and facilitates homeostatic proliferation of CD25(+) FoxP3(+) CD4(+) T cells. CD25(+) FoxP3(+) CD4(+) T cells may therefore constitute a suitable subset for HIV infection and plasma virion production. CD25(+) FoxP3(+) CD4(+) T cell frequencies, absolute numbers, and the expression of CCR5 and cell cycle marker Ki67 were studied in peripheral blood from HIV(+) and HIV(-) study volunteers. Different memory CD4(+) T cell subsets were then sorted for quantification of cell-associated HIV DNA and phylogenetic analyses of the highly variable EnvV1V3 region in comparison to plasma-derived virus sequences. In HIV(+) subjects, 51% (median) of CD25(+) FoxP3(+) CD4(+) T cells expressed the HIV coreceptor CCR5. Very high frequencies of Ki67(+) cells were detected in CD25(+) FoxP3(+) memory CD4(+) T cells (median, 27.6%) in comparison to CD25(-) FoxP3(-) memory CD4(+) T cells (median, 4.1%; P < 0.0001). HIV DNA content was 15-fold higher in CD25(+) FoxP3(+) memory CD4(+) T cells than in CD25(-) FoxP3(-) T cells (P = 0.003). EnvV1V3 sequences derived from CD25(+) FoxP3(+) memory CD4(+) T cells did not preferentially cluster with plasma-derived sequences. Quasi-identical cell-plasma sequence pairs were rare, and their proportion decreased with the estimated HIV infection duration. These data suggest that specific cellular characteristics of CD25(+) FoxP3(+) memory CD4(+) T cells might facilitate efficient HIV infection in vivo and passage of HIV DNA to cell progeny in the absence of active viral replication. The contribution of this cell population to plasma virion production remains unclear., Importance: Despite recent advances in the understanding of AIDS virus pathogenesis, which cell subsets support HIV infection and replication in vivo is incompletely understood. In vitro, the IL-2 signaling pathway and IL-2-dependent cell cycle induction are essential for HIV infection of stimulated T cells. CD25(+) FoxP3(+) memory CD4 T cells, often referred to as regulatory CD4 T cells, depend on IL-2 signaling for homeostatic proliferation in vivo Our results show that CD25(+) FoxP3(+) memory CD4(+) T cells often express the HIV coreceptor CCR5, are significantly more proliferative, and contain more HIV DNA than CD25(-) FoxP3(-) memory CD4 T cell subsets. The specific cellular characteristics of CD25(+) FoxP3(+) memory CD4(+) T cells probably facilitate efficient HIV infection in vivo and passage of HIV DNA to cell progeny in the absence of active viral replication. However, the contribution of this cell subset to plasma viremia remains unclear., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF
46. Correction: Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.
- Author
-
Kroidl I, Saathoff E, Maganga L, Clowes P, Maboko L, Hoerauf A, Makunde WH, Haule A, Mviombo P, Pitter B, Mgeni N, Mabuye J, Kowuor D, Mwingira U, Malecela MN, Löscher T, and Hoelscher M
- Abstract
[This corrects the article DOI: 10.1371/journal.pntd.0004618.].
- Published
- 2016
- Full Text
- View/download PDF
47. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.
- Author
-
Nicoli F, Chachage M, Clowes P, Bauer A, Kowour D, Ensoli B, Cafaro A, Maboko L, Hoelscher M, Gavioli R, Saathoff E, and Geldmacher C
- Subjects
- Adult, CD8-Positive T-Lymphocytes immunology, Cohort Studies, Disease Progression, Female, HIV Infections immunology, HIV Infections virology, Humans, Immunoglobulin A analysis, Immunoglobulin A blood, Immunoglobulin G analysis, Immunoglobulin G blood, Immunoglobulin M analysis, Immunoglobulin M blood, Lymphocyte Activation, Male, Tanzania, Viral Load, HIV Antibodies classification, HIV Infections pathology, HIV-1 immunology, tat Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Background: The presence of IgG and IgM against Tat, an HIV protein important for viral replication and immune dysfunction, is associated with slow disease progression in clade B HIV-infected individuals. However, although Tat activities strictly depend on the viral clade, our knowledge about the importance of anti-Tat antibodies in non-clade B HIV infection is poor. The objective of this study was to investigate the association of different anti-Tat antibody isotypes with disease progression in non-clade B HIV-infected subjects and to study the relationship between anti-Tat humoral responses and immunological abnormalities., Methods: Anti-clade B and -clade C Tat IgG, IgM and IgA titers were assessed in serum samples from 96 cART-naïve subjects with chronic HIV infection from Mbeya, Tanzania, and associated with CD4(+) T cell count, plasma viremia and CD4(+) and CD8(+) T cell phenotypes., Results: Anti-Tat IgM were preferentially detected in chronic HIV-infected subjects with low T cell activation (p-value = 0.03) and correlated with higher CD4(+) T cell counts and lower viral loads irrespective of the duration of infection (p-value = 0.019 and p-value = 0.037 respectively). Conversely, anti-Tat IgA were preferentially detected in individuals with low CD4(+) T cell counts and high viral load (p-value = 0.02 and p-value < 0.001 respectively). The simultaneous presence of anti-Tat IgG and IgM protected from fast CD4(+) T cell decline (p-value < 0.01) and accumulation of CD38(+)HLADR(+)CD8(+) T cells (p- value = 0.029)., Conclusions: Anti-Tat IgG alone are not protective in non-clade B infected subjects, unless concomitant with IgM, suggesting a protective role of persistent anti-Tat IgM irrespective of the infecting clade.
- Published
- 2016
- Full Text
- View/download PDF
48. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
- Author
-
Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Abdool Karim S, Abdool Karim Q, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, and Williamson C
- Subjects
- Antibodies, Monoclonal immunology, Antibodies, Monoclonal therapeutic use, Antibodies, Neutralizing immunology, Broadly Neutralizing Antibodies, Clinical Trials as Topic, HIV Antibodies, HIV Envelope Protein gp120 immunology, Humans, Immunization, Passive methods, Phylogeny, Vaccination methods, AIDS Vaccines immunology, HIV Infections immunology, HIV-1 genetics, HIV-1 immunology
- Abstract
The development of biomedical interventions to reduce acquisition of HIV-1 infection remains a global priority, however their potential effectiveness is challenged by very high HIV-1 envelope diversity. Two large prophylactic trials in high incidence, clade C epidemic regions in southern Africa are imminent; passive administration of the monoclonal antibody VRC01, and active immunization with a clade C modified RV144-like vaccines. We have created a large representative panel of C clade viruses to enable assessment of antibody responses to vaccines and natural infection in Southern Africa, and we investigated the genotypic and neutralization properties of recently transmitted clade C viruses to determine how viral diversity impacted antibody recognition. We further explore the implications of these findings for the potential effectiveness of these trials. A panel of 200 HIV-1 Envelope pseudoviruses was constructed from clade C viruses collected within the first 100 days following infection. Viruses collected pre-seroconversion were significantly more resistant to serum neutralization compared to post-seroconversion viruses (p = 0.001). Over 13 years of the study as the epidemic matured, HIV-1 diversified (p = 0.0009) and became more neutralization resistant to monoclonal antibodies VRC01, PG9 and 4E10. When tested at therapeutic levels (10ug/ml), VRC01 only neutralized 80% of viruses in the panel, although it did exhibit potent neutralization activity against sensitive viruses (IC50 titres of 0.42 μg/ml). The Gp120 amino acid similarity between the clade C panel and candidate C-clade vaccine protein boosts (Ce1086 and TV1) was 77%, which is 8% more distant than between CRF01_AE viruses and the RV144 CRF01_AE immunogen. Furthermore, two vaccine signature sites, K169 in V2 and I307 in V3, associated with reduced infection risk in RV144, occurred less frequently in clade C panel viruses than in CRF01_AE viruses from Thailand. Increased resistance of pre-seroconversion viruses and evidence of antigenic drift highlights the value of using panels of very recently transmitted viruses and suggests that interventions may need to be modified over time to track the changing epidemic. Furthermore, high divergence such as that observed in the older clade C epidemic in southern Africa may impact vaccine efficacy, although the correlates of infection risk are yet to be defined in the clade C setting. Findings from this study of acute/early clade C viruses will aid vaccine development, and enable identification of new broad and potent antibodies to combat the HIV-1 C-clade epidemic in southern Africa.
- Published
- 2016
- Full Text
- View/download PDF
49. Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
- Author
-
Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandström E, Kroidl A, Bakari M, Nilsson C, and McCormack S
- Subjects
- AIDS Vaccines adverse effects, AIDS Vaccines genetics, Adolescent, Adult, Antibodies, Neutralizing immunology, Antibody-Dependent Cell Cytotoxicity, Female, HIV Antibodies immunology, HIV-1 genetics, Healthy Volunteers, Humans, Immunization Schedule, Immunoglobulin G immunology, Interferon-gamma blood, Lymphocyte Activation, Male, Neutralization Tests, Tanzania, Vaccination, Vaccines, DNA adverse effects, Young Adult, AIDS Vaccines immunology, Adjuvants, Immunologic, Glucosides, HIV Infections immunology, HIV Infections prevention & control, HIV-1 immunology, Immunization, Secondary, Lipid A, Vaccines, DNA immunology, Viral Vaccines, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Background: A vaccine against HIV is widely considered the most effective and sustainable way of reducing new infections. We evaluated the safety and impact of boosting with subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid adjuvant (GLA-AF) in Tanzanian volunteers previously given three immunizations with HIV-DNA followed by two immunizations with recombinant modified vaccinia virus Ankara (HIV-MVA)., Methods: Forty volunteers (35 vaccinees and five placebo recipients) were given two CN54rgp140/GLA-AF immunizations 30-71 weeks after the last HIV-MVA vaccination. These immunizations were delivered intramuscularly four weeks apart., Results: The vaccine was safe and well tolerated except for one episode of asymptomatic hypoglycaemia that was classified as severe adverse event. Two weeks after the second HIV-MVA vaccination 34 (97%) of the 35 previously vaccinated developed Env-specific binding antibodies, and 79% and 84% displayed IFN-γ ELISpot responses to Gag and Env, respectively. Binding antibodies to subtype C Env (included in HIV-DNA and protein boost), subtype B Env (included only in HIV-DNA) and CRF01_AE Env (included only in HIV-MVA) were significantly boosted by the CN54rgp140/GLA-AF immunizations. Functional antibodies detected using an infectious molecular clone virus/peripheral blood mononuclear cell neutralization assay, a pseudovirus/TZM-bl neutralization assay or by assays for antibody-dependent cellular cytotoxicity (ADCC) were not significantly boosted. In contrast, T-cell proliferative responses to subtype B MN antigen and IFN-γ ELISpot responses to Env peptides were significantly enhanced. Four volunteers not primed with HIV-DNA and HIV-MVA before the CN54rgp140/GLA-AF immunizations mounted an antibody response, while cell-mediated responses were rare. After the two Env subtype C protein immunizations, a trend towards higher median subtype C Env binding antibody titers was found in vaccinees who had received HIV-DNA and HIV-MVA prior to the two Env protein immunizations as compared to unprimed vaccinees (p = 0.07)., Conclusion: We report excellent tolerability, enhanced binding antibody responses and Env-specific cell-mediated immune responses but no ADCC antibody increase after two immunizations with a subtype C rgp140 protein adjuvanted in GLA-AF in healthy volunteers previously immunized with HIV-DNA and HIV-MVA., Trial Registration: International Clinical Trials Registry PACTR2010050002122368.
- Published
- 2016
- Full Text
- View/download PDF
50. Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.
- Author
-
Kroidl I, Saathof E, Maganga L, Clowes P, Maboko L, Hoerauf A, Makunde WH, Haule A, Mviombo P, Pitter B, Mgeni N, Mabuye J, Kowuor D, Mwingira U, Malecela MN, Löscher T, and Hoelscher M
- Subjects
- Animals, Antigens, Protozoan blood, Coinfection drug therapy, Humans, Prevalence, Tanzania epidemiology, Treatment Outcome, Wuchereria bancrofti drug effects, Wuchereria bancrofti isolation & purification, Albendazole therapeutic use, Elephantiasis, Filarial drug therapy, Elephantiasis, Filarial epidemiology, Filaricides therapeutic use, HIV Infections complications, Ivermectin therapeutic use
- Abstract
Background: Annual mass treatment with ivermectin and albendazole is used to treat lymphatic filariasis in many African countries, including Tanzania. In areas where both diseases occur, it is unclear whether HIV co-infection reduces treatment success., Methodology: In a general population study in Southwest Tanzania, individuals were tested for HIV and circulating filarial antigen, an indicator of Wuchereria bancrofti adult worm burden, before the first and after 2 consecutive rounds of anti-filarial mass drug administration., Principle Findings: Testing of 2104 individuals aged 0-94 years before anti-filarial treatment revealed a prevalence of 24.8% for lymphatic filariasis and an HIV-prevalence of 8.9%. Lymphatic filariasis was rare in children, but prevalence increased in individuals above 10 years, whereas a strong increase in HIV was only seen above 18 years of age. The prevalence of lymphatic filariasis in adults above 18 years was 42.6% and 41.7% (p = 0.834) in HIV-negatives and-positives, respectively. Similarly, the HIV prevalence in the lymphatic filariasis infected (16.6%) and uninfected adult population (17.1%) was nearly the same. Of the above 2104 individuals 798 were re-tested after 2 rounds of antifilarial treatment. A significant reduction in the prevalence of circulating filarial antigen from 21.6% to 19.7% was found after treatment (relative drop of 8.8%, McNemar's exact p = 0.036). Furthermore, the post-treatment reduction of CFA positivity was (non-significantly) larger in HIV-positives than in HIV-negatives (univariable linear regression p = 0.154)., Conclusion/significance: In an area with a high prevalence for both diseases, no difference was found between HIV-infected and uninfected individuals regarding the initial prevalence of lymphatic filariasis. A moderate but significant reduction in lymphatic filariasis prevalence and worm burden was demonstrated after two rounds of treatment with albendazole and ivermectin. Treatment effects were more pronounced in the HIV co-infected subgroup, indicating that the effectiveness of antifilarial treatment was not reduced by concomitant HIV-infection. Studies with longer follow-up time could validate the observed differences in treatment effectiveness.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.